Autologous Cell Therapies for Cerebral Palsy

This is a randomized, blinded, placebo-controlled, cross-over study designed to treat cerebral palsy in pediatric patients with an infusion of autologous bone marrow mononuclear cells or autologous umbilical cord blood cells. Neuroimaging data are acquired on a 3T GE clinical MRI scanner at three time points: baseline, 6 months, and 12 months post infusion. Quantitative analysis of neuroimaging data targets major white matter pathways such as the corpus callosum and the corticospinal tract. These quantitative measures are then correlated with such functional outcomes as gross motor function and a battery of neuropsychological assessments.